Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Gilead Sciences |
---|---|
Information provided by: | Gilead Sciences |
ClinicalTrials.gov Identifier: | NCT00670657 |
Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
Condition | Intervention | Phase |
---|---|---|
Candidemia Invasive Candidiasis |
Drug: AmBisome |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | CRITIC: Phase II Pilot Multicenter Study on Efficacy and Safety of Liposomal Amphotericin B (AmBisome®) at 2 mg/kg/Day in the Treatment of Candidemia and Invasive Candidiasis in Non-Neutropenic Patients |
Estimated Enrollment: | 39 |
Study Start Date: | May 2007 |
Study Completion Date: | January 2009 |
Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
AmBisome® 2 mg/kg/day in a unique daily IV administration
|
Drug: AmBisome
Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
|
Subjects will be enrolled to receive intravenously AmBisome® at 2 mg/kg/day for a maximum of 4 weeks. Treatment will be discontinued in case of failure, adverse events precluding treatment or success. In case of success AmBisome® at 2 mg/kg/day should be administered for at least 5 days after the complete resolution of all clinical findings of an active infection or for at least 8 days after the last positive blood culture or culture from a normally sterile site. It is not recommended to declare failure (and therefore change treatment) before giving at least 5 days of antifungal therapy. Failures in patients given less than 5 days of treatment should be well documented (e.g. persistent positive cultures despite catheter removal, clinical deterioration in absence of any explanation other than the fungal infection). Follow-up evaluations will be conducted at 2 and 4 weeks after the end of AmBisome® therapy. At end of treatment (time point for success or failure) patients may be shifted to oral (not intravenous) antifungals at the discretion of the local investigator, once a complete response has been achieved, if secondary prophylaxis is deemed necessary.
Ages Eligible for Study: | 14 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Subjects who have clinical evidence of infection AT SOME TIME WITHIN 48 HOURS PRIOR TO ENROLLMENT, including AT LEAST ONE of the following:
Exclusion Criteria:
Subjects with moderate or severe liver disease defined as any one or more of the following:
Responsible Party: | Gilead Sciences ( Luigi Antonio Picaro ) |
Study ID Numbers: | GS-IT-131-0177 |
Study First Received: | April 29, 2008 |
Last Updated: | March 26, 2009 |
ClinicalTrials.gov Identifier: | NCT00670657 History of Changes |
Health Authority: | Italy: National Institute of Health |
candidemia invasive candidiasis Ambisome liposomal amphotericin B |
Abelcet Anti-Bacterial Agents Anti-Infective Agents Amphotericin B |
Mycoses Candidiasis Antifungal Agents Liposomal amphotericin B |
Abelcet Amphotericin B Anti-Infective Agents Antiprotozoal Agents Candidiasis Liposomal amphotericin B Pharmacologic Actions |
Mycoses Anti-Bacterial Agents Antiparasitic Agents Therapeutic Uses Antifungal Agents Antibiotics, Antifungal Amebicides |